---
id: 067
title: Amphotericin B Mechanism and Spectrum
category: antimicrobials
subcategory: amphotericin_b
tags: [amphotericin-B, polyene, ergosterol, fungicidal, broadest-spectrum]
difficulty: medium
---

## Question

What is amphotericin B's mechanism and spectrum? Use the **"AMPHO = BROADEST Antifungal"** mnemonic.

## Answer

### **"AMPHO = BROADEST Antifungal" Mnemonic:**

**AMPHO:**
- **A**ll fungi covered (broadest spectrum)
- **M**embrane pore formation
- **P**olyene antibiotic
- **H**ighly toxic (nephrotoxic)
- **O**nly fungicidal antifungal (besides echin for *Candida*)

**BROADEST:**
- **B**inds ergosterol (not enzyme)
- **R**apid fungicidal effect
- **O**nly antifungal for mucor (1st-line)
- **A**ll endemic fungi covered
- **D**eoxycholate vs liposomal forms
- **E**xcellent for severe infections
- **S**alts (K+, Mg2+) wasting
- **T**oxicity limits use (renal, infusion reactions)

### **Mechanism of Action:**

**Target:** **Ergosterol** (in fungal cell membrane - NOT an enzyme)

**Process:**
1. Ampho B **binds directly to ergosterol** in fungal membrane
2. Forms **transmembrane pores/channels**
3. **Ion leakage** (K+, other ions) → loss of membrane integrity
4. **Cell death** (fungicidal)

**Unique:** Only antifungal that binds to the **end product (ergosterol)** rather than inhibiting its synthesis

**Selectivity:** Fungi use ergosterol; humans use cholesterol. Ampho B has higher affinity for ergosterol, but some cholesterol binding occurs → **human toxicity**

### **Spectrum (Broadest of All Antifungals):**

| Organism | Activity | Notes |
|----------|----------|-------|
| ***Candida*** spp. | Fungicidal | All species (including *C. auris*) |
| ***Cryptococcus*** | Fungicidal | 1st-line for meningitis |
| ***Aspergillus*** | Fungicidal | Alternative (vori 1st-line) |
| **Mucorales** (mucor) | Fungicidal | **1st-line** (only reliable option) |
| ***Histoplasma*** | Fungicidal | 1st-line for severe disease |
| ***Blastomyces*** | Fungicidal | 1st-line for severe disease |
| ***Coccidioides*** | Fungicidal | 1st-line for severe disease |
| ***Sporothrix*** | Fungicidal | Alternative |
| ***Fusarium*** | Fungicidal | Alternative |
| ***Scedosporium*** | Variable | Less reliable |

**Key Point:** **ONLY reliable antifungal for mucormycosis** (vori/fluconazole have NO activity)

## Key Points

### **Formulations:**

| Formulation | Nephrotoxicity | Cost | Notes |
|-------------|----------------|------|-------|
| **Ampho B deoxycholate** | **High (30-80%)** | Cheap | "Conventional" formulation |
| **Liposomal ampho B** (AmBisome) | **Lower (15-20%)** | **Very expensive** | Preferred formulation |
| **Ampho B lipid complex** (Abelcet) | Moderate (20-40%) | Expensive | Less used |
| **Ampho B colloidal dispersion** (Amphotec) | Moderate | Expensive | Rarely used |

**Clinical Pearl:** **Liposomal ampho B** (L-AmB) is preferred formulation - dramatically reduces nephrotoxicity while maintaining efficacy

### **Dosing:**

**Liposomal Amphotericin B (L-AmB):**
- **Standard dose:** 3-5 mg/kg IV daily
- **Mucormycosis:** **5-10 mg/kg IV daily** (high-dose)
- **Cryptococcal meningitis:** 3-4 mg/kg IV daily (+ flucytosine)

**Amphotericin B Deoxycholate:**
- 0.5-1.0 mg/kg IV daily
- **Test dose:** 1 mg over 30 min (watch for anaphylaxis - rare)
- Infuse over 4-6 hours

### **Clinical Indications (When to Use Ampho B):**

**First-Line:**
- **Mucormycosis** (ONLY reliable option)
- **Severe endemic mycoses** (*Histoplasma*, *Blastomyces*, *Coccidioides*)
- **Cryptococcal meningitis** (induction therapy + flucytosine)

**Alternative/Salvage:**
- Invasive aspergillosis (if azole failure/intolerance)
- Refractory candidemia
- *C. auris* infections (many azole-resistant)

### **Clinical Pearls:**
- **Broadest spectrum** antifungal available
- **Only fungicidal** polyene (others are azoles/echin)
- **1st-line for mucor** (posaconazole alternative if intolerant)
- **Liposomal form** dramatically reduces nephrotoxicity (15-20% vs 30-80%)
- **High-dose L-AmB** (10 mg/kg) for mucor has better outcomes
- **Cost** is major barrier to liposomal formulation

## Sources

- [StatPearls NBK482327: Amphotericin B]
- [PMC4856207: Liposomal Amphotericin B Review]
- [PMC6369474: Renal Recovery from L-AmB Nephrotoxicity]

## Media

N/A
